Tourmaline Bio, Inc.

Contributing Author

Recent Articles by Tourmaline Bio, Inc.

Sep-09	Tourmaline Bio Enters into Agreement to be Acquired by Novartis AG TRML GlobeNewswire
Aug-31	Tourmaline Bio Presents Data from the Ongoing Phase 2 TRANQUILITY Trial at the 2025 European Society of Cardiology Congress TRML GlobeNewswire
Aug-13	Tourmaline Bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights TRML GlobeNewswire
May-20	Tourmaline Bio Announces Positive Topline Results from the Ongoing Phase 2 TRANQUILITY Trial Evaluating Pacibekitug in Patients with Elevated High-Sensitivity C-reactive Protein and Chronic Kidney Disease TRML GlobeNewswire
May-19	Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025 TRML GlobeNewswire
May-02	Tourmaline Bio Reports First Quarter 2025 Financial Results and Recent Business Highlights TRML GlobeNewswire